These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 20000882

  • 21. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.
    Majewski S, Slomka S, Zielinska-Wyderkiewicz E, Ciebiada M, Gorski P.
    Am J Cardiovasc Drugs; 2012 Jun 01; 12(3):179-88. PubMed ID: 22409211
    [Abstract] [Full Text] [Related]

  • 22. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM.
    Am J Cardiovasc Drugs; 2012 Dec 01; 12(6):415-26. PubMed ID: 23181944
    [Abstract] [Full Text] [Related]

  • 23. Characterization of an ambulatory population with stable coronary artery disease and importance of heart rate: the PULSAR registry.
    Seabra-Gomes R, Investigadores do Registo PULSAR.
    Rev Port Cardiol; 2010 Apr 01; 29(4):483-508. PubMed ID: 20734572
    [Abstract] [Full Text] [Related]

  • 24. Ivabradine: recent and potential applications in clinical practice.
    Riccioni G.
    Expert Opin Pharmacother; 2011 Feb 01; 12(3):443-50. PubMed ID: 21254949
    [Abstract] [Full Text] [Related]

  • 25. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
    Danchin N, Cucherat M, Thuillez C, Durand E, Kadri Z, Steg PG.
    Arch Intern Med; 2006 Apr 10; 166(7):787-96. PubMed ID: 16606817
    [Abstract] [Full Text] [Related]

  • 26. Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction.
    Reil JC, Reil GH, Böhm M.
    Trends Cardiovasc Med; 2009 Jul 10; 19(5):152-7. PubMed ID: 20005474
    [Abstract] [Full Text] [Related]

  • 27. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA, Molnar J, Arora RR.
    Diabetes Obes Metab; 2008 Jan 10; 10(1):41-52. PubMed ID: 18095949
    [Abstract] [Full Text] [Related]

  • 28. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S, Davis BR, Braunwald E, Rouleau JL, Dagenais GR, Sussex B, Steingart RM, Brown EJ, Lamas GA, Gordon D, Bernstein V, Pfeffer MA, Survival and Ventricular Enlargement Trial.
    Am Heart J; 2004 Aug 10; 148(2):356-64. PubMed ID: 15309009
    [Abstract] [Full Text] [Related]

  • 29. Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction.
    Cammarano C, Silva M, Comee M, Donovan JL, Malloy MJ.
    Clin Ther; 2016 Feb 10; 38(2):387-95. PubMed ID: 26839043
    [Abstract] [Full Text] [Related]

  • 30. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
    Magrini G, Nicolosi GL, Chiariello M, Ferrari R, Remme P, Tavazzi L.
    Ital Heart J; 2005 Nov 10; 6 Suppl 7():14S-23S. PubMed ID: 16485513
    [Abstract] [Full Text] [Related]

  • 31. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction.
    Murcia AM, Hennekens CH, Lamas GA, Jiménez-Navarro M, Rouleau JL, Flaker GC, Goldman S, Skali H, Braunwald E, Pfeffer MA.
    Arch Intern Med; 2004 Nov 08; 164(20):2273-9. PubMed ID: 15534166
    [Abstract] [Full Text] [Related]

  • 32. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure.
    Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R.
    Am Heart J; 2013 Oct 08; 166(4):654-661.e6. PubMed ID: 24093844
    [Abstract] [Full Text] [Related]

  • 33. Ivabradine in stable coronary artery disease without clinical heart failure.
    Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R, SIGNIFY Investigators.
    N Engl J Med; 2014 Sep 18; 371(12):1091-9. PubMed ID: 25176136
    [Abstract] [Full Text] [Related]

  • 34. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India.
    J Assoc Physicians India; 2006 Jun 18; 54():469-80. PubMed ID: 16909697
    [Abstract] [Full Text] [Related]

  • 35. Limited role for ivabradine in the treatment of chronic heart failure.
    Cullington D, Goode KM, Cleland JG, Clark AL.
    Heart; 2011 Dec 18; 97(23):1961-6. PubMed ID: 21917660
    [Abstract] [Full Text] [Related]

  • 36. The HOPE Study (Heart Outcomes Prevention Evaluation).
    Sleight P.
    J Renin Angiotensin Aldosterone Syst; 2000 Mar 18; 1(1):18-20. PubMed ID: 11967789
    [Abstract] [Full Text] [Related]

  • 37. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers.
    Flannery G, Gehrig-Mills R, Billah B, Krum H.
    Am J Cardiol; 2008 Mar 15; 101(6):865-9. PubMed ID: 18328855
    [Abstract] [Full Text] [Related]

  • 38. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S, Bakir SE.
    Drugs; 2000 Mar 15; 59 Spec No 2():25-37. PubMed ID: 11002856
    [Abstract] [Full Text] [Related]

  • 39. [Ivabradine in patients with stable ischemic heart disease and left ventricular systolic dysfunction: the results of the BEAUTIFUL study].
    Filipovský J.
    Vnitr Lek; 2009 May 15; 55(5):513-6. PubMed ID: 19514618
    [Abstract] [Full Text] [Related]

  • 40. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study.
    Ekman I, Chassany O, Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Swedberg K.
    Eur Heart J; 2011 Oct 15; 32(19):2395-404. PubMed ID: 21875859
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.